Fig. 3 | Scientific Reports

Fig. 3

From: Presence of liver metastasis correlated with high tumor abundance and indicated adverse prognostic feature in EGFR mutation non-small-cell lung cancer patients

Fig. 3

Progression-free survival and overall survival in patients with EGFR-mutant NSCLC according to dynamic change of ctDNA status during EGFR-TKI treatment. (A) PFS (10.4 months for patients who had switched from detectable to undetectable ctDNA, and 7.3 months for patients who continued to have detectable ctDNA; p = 0.06). (B) OS (19 months for patients who had changed from detectable to undetectable ctDNA, and 9.7 months for patients who continued to have detectable ctDNA; p < 0.001). Statistical significance (*, p < 0.05).

Back to article page